Mission & Vision
Our mission is to develop novel biological drugs and personalized therapies to address unmet challenges in human diseases providing innovative solutions based on the microbiota. We are a preclinical stage company developing novel biological drugs, based on commensal bacteria, targeting infectious diseases. Our lead candidate, MVT-201, is an orally administered capsule generated under cGMP conditions that represents the complete microbiota ecosystem and will enter clinical trials in Q4 2023.
Microviable´s PharmaBiota® platform enabled the creation of a large and diverse bacterial strain collection with thousands of isolates to generate a second category of biological products based on our fully integrated R&D capabilities. With another 4 preclinical programs ongoing, we are leveraging the microbiota to improve the patients´ quality of life. In addition to our internal programs, Microviable has an established partnership with Inmunomet Intolerancias y Disbiosis to develop microbiota therapies as personalized medicine.
You can follow the latest news of MicroViable in this section
Microviable will be presenting at the Microbiome & Probiotic R&D & Business Collaboration Forum
Microviable Therapeutics will be presenting at the Microbiome & Probiotic R&D & Business Collaboration Forum [...]
Microviable will be attending the Microbiome & Probiotic R&D & Business Collaboration Forum
Microviable Therapeutics is thrilled to announce that will be attending the Microbiome & Probiotic R&D [...]
Microviable Therapeutics welcomes our internship student Alejandro Ojeda
Microviable welcomes to the team our new internship student Alejandro Ojeda Suárez, Biologist with a [...]
Get in touch with us for any questions using the following contact form.